Energenesis Biomedical Co., Ltd. to Present DFU Therapy at EWMA 2026

Energenesis Biomedical Co., Ltd, a clinical-stage biotech company developing therapies aimed at restoring cellular energy, has announced that it will showcase clinical application data for its investigational treatment ENERGI-F703DFU at the European Wound Management Association 2026 Annual Conference, taking place in Bremen from May 5–7, 2026.

As part of EWMA 2026, the company will deliver a presentation titled “ENERGI-F703DFU Gel: A Novel Topical Drug for the Treatment of Diabetic Foot Ulcers — Clinical Case Sharing.” The session is set for Wednesday, May 6, 2026, between 14:35 and 14:50 CEST during the New Tech Industry Symposium at the EWMA Arena. During the presentation, Energenesis will highlight real-world clinical case experiences illustrating how ENERGI-F703DFU may help accelerate wound closure and enhance recovery in patients suffering from chronic diabetic foot ulcers that are resistant to healing.